EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Harnessing Cytomegalovirus DNAemia and CMV-Specific Cell-Mediated Immunity in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients

Sanghoon Lee iD, Gahee Kim iD, Jung Hwa Kim iD, Eun Seok Choi iD, Sung Han Kang iD, Hyery Kim iD, Kyung-Nam Koh iD, Ho Joon Im iD, Jina Lee iD

Journal of Korean Medical Science · 2026

DOI: 10.3346/jkms.2026.41.e86 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Korean Medical Science, 2026. Verfasst von Sanghoon Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections, Cytomegalovirus, Immunity, Cellular. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Asan Institute for Life Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Recovery via cytomegalovirus (CMV)-specific cell-mediated immunity (CMI) in pediatric hematopoietic stem cell transplantation (HSCT) recipients is associated with a lower incidence of significant CMV DNAemia and disease. This study aimed to determine whether early post-HSCT CMI monitoring could predict CMV infection outcomes and identify factors that influence CMI recovery. METHODS: Pediatric patients (≤ 19 years) undergoing allogeneic HSCT at Asan Medical Center Children's Hospital between August 2018 and February 2020 were prospectively enrolled. CMV-specific CMI was assessed using the enzyme-linked immunospot assay for phosphoprotein 65 (pp65) or immediate-early protein 1 (IE-1) antigens at pre-transplantation, and 1 and 3 months post-transplantation. Plasma CMV polymerase chain reaction monitoring was conducted regularly, and the incidence of CMV DNAemia and CMV disease was evaluated over a two-year follow-up period. RESULTS: Of the 55 enrolled pediatric recipients, CMV DNAemia occurred in 74.5%, with 21.8% of cases progressing to significant CMV DNAemia. Cumulative CMI recovery rates at 3 months were 61.8% for pp65 and 43.6% for IE-1. Recipients with a cumulative recovery of pp65-specific CMI exhibited a significantly lower incidence of significant CMV DNAemia and CMV disease. In contrast, the cumulative recovery of IE-1-specific CMI was not associated with CMV outcomes. In the multivariate analysis, haploidentical donor status and post-HSCT CMV DNAemia were independently associated with impaired cumulative recovery of both pp65- and IE-1-specific CMI. CONCLUSION: Monitoring pp65-specific CMI recovery within three months post-HSCT is valuable for predicting significant CMV infection in pediatric recipients. Haploidentical HSCT recipients demonstrated impaired CMI recovery, highlighting the need for careful monitoring and tailored prophylactic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationCytomegalovirus InfectionsCytomegalovirusImmunity, CellularDNA, ViralHumansFemaleChildMaleTransplantation, HomologousPhosphoproteinsAdolescentChild, PreschoolInfantViral Matrix ProteinsProspective StudiesImmediate-Early ProteinsEnzyme-Linked Immunospot Assay

Stichwörter der Autor:innen

Allogeneic Hematopoietic Stem Cell TransplantationCell-Mediated ImmunityCytomegalovirusEnzyme-Linked Immunospot AssayPediatric Recipients

Substanzen

DNA, ViralPhosphoproteinsViral Matrix ProteinsImmediate-Early Proteinscytomegalovirus matrix protein 65kDa

Autor:innen und Institutionen

  • Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Pediatrics, Chonnam National University Hospital, Gwangju, Korea.
  • Department of Pediatrics, Chosun University Hospital, Gwangju, Korea.
  • Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea. entier@amc.seoul.kr.

ORCID-Profile: Sanghoon Lee, Gahee Kim, Jung Hwa Kim, Eun Seok Choi, Sung Han Kang, Hyery Kim, Kyung-Nam Koh, Ho Joon Im, Jina Lee

Förderung

  • Asan Institute for Life Sciences

Zitieren

APA

Lee, S., Kim, G., Kim, J. H., Choi, E. S., Kang, S. H., Kim, H., Koh, K. N., Im, H. J., & Lee, J. (2026). Harnessing Cytomegalovirus DNAemia and CMV-Specific Cell-Mediated Immunity in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients. Journal of Korean Medical Science. https://doi.org/10.3346/jkms.2026.41.e86

Vancouver

Lee S, Kim G, Kim JH, Choi ES, Kang SH, Kim H, et al. Harnessing Cytomegalovirus DNAemia and CMV-Specific Cell-Mediated Immunity in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients. Journal of Korean Medical Science. 2026. doi:10.3346/jkms.2026.41.e86

BibTeX
@article{Lee2026,
  author = {Lee, Sanghoon and Kim, Gahee and Kim, Jung Hwa and Choi, Eun Seok and Kang, Sung Han and Kim, Hyery and Koh, Kyung-Nam and Im, Ho Joon and Lee, Jina},
  title = {Harnessing Cytomegalovirus DNAemia and CMV-Specific Cell-Mediated Immunity in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients},
  journal = {Journal of Korean Medical Science},
  year = {2026},
  doi = {10.3346/jkms.2026.41.e86}
}
Kostenlos starten →